Clinical Trials · NCT07782840
QL1706 Plus Neoadjuvant Endocrine Therapy in HR-Positive/HER2-Negative Breast Cancer With a Poor Response to Neoadjuvant Chemotherapy
- Phase
- Phase 2
- Recruitment status
- Not Yet Recruiting
- Sponsor
- Hebei Medical University Fourth Hospital
- Enrollment
- 40
- Start date
- Oct 2026
- Locations
- See registry
- Primary endpoint
- Objective Response Rate (ORR)